A preliminary single-centre, randomised, comparative study of the Eakin wound dressing in the management of superficial/partial thickness wounds

Submission date	Recruitment status	[X] Prospectively registered
11/05/2005	No longer recruiting	☐ Protocol
Registration date	Overall study status	Statistical analysis plan
15/06/2005	Completed	☐ Results
Last Edited	Condition category	Individual participant data
07/03/2017	Skin and Connective Tissue Diseases	Record updated in last year

Plain English summary of protocol

Not provided at time of registration

Contact information

Type(s)

Scientific

Contact name

Mr Denis Harkin

Contact details

Royal Group of Hospitals Trust Grosvenor Road Belfast United Kingdom BT12 6BA

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers

TGE - W01

Study information

Scientific Title

A preliminary single-centre, randomised, comparative study of the Eakin wound dressing in the management of superficial/partial thickness wounds

Study objectives

Eakin wound dressing is effective and safe for use on humans with superficial/partial thickness wounds.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Not provided at time of registration

Study design

Single-centre randomised controlled trial

Primary study design

Interventional

Secondary study design

Randomised controlled trial

Study setting(s)

Hospital

Study type(s)

Treatment

Participant information sheet

Health condition(s) or problem(s) studied

Wounds

Interventions

Eakin wound dressing will be trialled against a leading hydrocolloid wound dressing for a period of 5 weeks or until the wound has healed. Dressings will be changed every 4 days.

Intervention Type

Drug

Phase

Not Specified

Drug/device/biological/vaccine name(s)

Eakin wound dressing

Primary outcome measure

Confirmation of the clinical efficacy and safety of Eakin wound dressing when used in the treatment of superficial/partial thickness wounds. Wound is healed (or reduced in size) over a period of 5 weeks.

Secondary outcome measures

Not provided at time of registration

Overall study start date

01/10/2005

Completion date

31/01/2006

Eligibility

Key inclusion criteria

All patients presenting superficial/partial thickness wounds which could or would normally be treated with a 'hydrocolloid' wound dressing, and who are not precluded by the exclusion criteria below, will be invited to participate in this clinical trial.

Participant type(s)

Patient

Age group

Adult

Sex

Both

Target number of participants

40 hospital patients

Key exclusion criteria

Patients will be excluded from the trial under the following circumstances:

- 1. Wound is >5 cm length or breadth
- 2. Wound is >0.5 cm depth
- 3. Wound involving muscle, tendon or bone
- 4. Wound infection is suspected
- 5. Where informed consent is withheld
- 6. Where patients are unable to give informed consent due to legal incompetence, unless informed consent is available from a responsible relative or guardian
- 7. Where, in the physician's opinion, inclusion in the trial is not advised

Date of first enrolment

01/10/2005

Date of final enrolment

31/01/2006

Locations

Countries of recruitment

Northern Ireland

United Kingdom

Study participating centre Royal Group of Hospitals Trust Belfast United Kingdom BT12 6BA

Sponsor information

Organisation

TG Eakin Limited (UK)

Sponsor details

15 Ballystockart Road Comber United Kingdom BT23 5QY

Sponsor type

Industry

Website

http://www.eakin.co.uk/home.asp

Funder(s)

Funder type

Industry

Funder Name

Full cost of trial will be funded by TG Eakin Limited (UK)

Results and Publications

Publication and dissemination plan

Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration